Study guide
9.2 Anaphylaxis & Allergic Emergencies
Arab Board Pediatrics Part 1 Written Examination ABHS
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current ABHS Pediatrics Part 1 Exam Facts 1.2 How to Use This Guide & Part 1 Study Strategy
2 Neonatal Care I
2.1 Delivery-Room Management & Neonatal Resuscitation 2.2 Prematurity & Complications of Prematurity 2.3 Neonatal Jaundice & Hyperbilirubinemia
3 Neonatal Care II
3.1 Neonatal Sepsis & Infections 3.2 Neonatal Hypoglycemia & Metabolic Problems 3.3 Common Newborn Problems, Birth Injury & Screening
4 Infectious Diseases
4.1 Fever Without a Source & Sepsis Evaluation 4.2 Viral Exanthems & Common Childhood Infections 4.3 TORCH & Congenital Infections 4.4 Tuberculosis & Chronic/Unusual Pediatric Infections
5 Immunization
5.1 Routine Immunization Schedule & Vaccine Science 5.2 Contraindications, Adverse Events & Special Populations
6 Allergy & Immunology
6.1 Primary Immunodeficiency 6.2 Allergic Disease & Atopy
7 Growth & Development
7.1 Developmental Milestones & Red Flags 7.2 Growth Assessment & Failure to Thrive 7.3 Corrected Age & Preterm Follow-Up 7.4 Developmental & Behavioral Disorders
8 Nutrition
8.1 Breastfeeding & Infant Feeding 8.2 Weaning & Malnutrition 8.3 Micronutrient Deficiencies (Rickets, Iron Deficiency)
9 Pediatric Emergencies I
9.1 Pediatric Basic & Advanced Life Support 9.2 Anaphylaxis & Allergic Emergencies 9.3 Poisoning & Toxicology
10 Pediatric Emergencies II
10.1 Septic Shock & the Critically Ill Child 10.2 Upper Airway Emergencies (Epiglottitis, Foreign Body) 10.3 Non-Accidental Injury & Safeguarding
11 Cardiology
11.1 Cyanotic Congenital Heart Disease 11.2 Acyanotic Congenital Heart Disease & Heart Failure 11.3 Innocent Murmurs & Cardiac Evaluation 11.4 Rheumatic Fever & Acquired Heart Disease
12 Respiratory
12.1 Asthma 12.2 Bronchiolitis & Croup 12.3 Foreign Body Aspiration & Other Airway Disorders
13 Gastroenterology
13.1 Pyloric Stenosis & Vomiting Disorders 13.2 Intussusception & the Surgical Abdomen 13.3 Celiac Disease & Malabsorption 13.4 Hirschsprung Disease & Biliary Atresia
14 Nephrology & Genitourinary
14.1 Nephrotic Syndrome 14.2 Glomerulonephritis & Hematuria 14.3 UTI, Enuresis & Genitourinary Anomalies
15 Hematology & Oncology
15.1 Pediatric Anemias (Iron Deficiency, Thalassemia) 15.2 Sickle Cell Disease 15.3 Leukemia & Childhood Malignancies (incl. Wilms Tumor) 15.4 Bleeding & Platelet Disorders (ITP) & G6PD Deficiency
16 Endocrinology
16.1 Diabetes Mellitus & Diabetic Ketoacidosis 16.2 Thyroid & Adrenal Disorders 16.3 Growth Disorders & Puberty
17 Neurology
17.1 Febrile Seizures 17.2 Epilepsy Syndromes & Status Epilepticus 17.3 Bacterial Meningitis & CNS Infections 17.4 Neuromuscular Disorders & Headache
18 Genetics, Dysmorphology & Metabolism
18.1 Chromosomal Disorders & Dysmorphology 18.2 Inheritance Patterns, Consanguinity & Inborn Errors of Metabolism
19 Fluids, Electrolytes & Pharmacology
19.1 Maintenance Fluids & Dehydration 19.2 Electrolyte Disturbances 19.3 Pediatric Pharmacology & Prescribing/Dosing
20 Dermatology, ENT, Ophthalmology & Musculoskeletal
20.1 Common Pediatric Dermatology 20.2 ENT Disorders 20.3 Ophthalmology (Strabismus, Red Eye, Leukocoria) 20.4 Musculoskeletal & Rheumatologic Disorders
21 Adolescent Medicine & Ethics
21.1 Adolescent Health & Puberty 21.2 Ethics, Consent & Professionalism in Pediatrics
22 Final Review & Exam Strategy
22.1 High-Yield Numbers, Mnemonics & Cross-Topic Review 22.2 Exam-Day Strategy & Time Management
9.2 Anaphylaxis & Allergic Emergencies
Key Takeaways Explain This Topic AI
Anaphylaxis can be diagnosed without any skin or mucosal findings if hypotension follows exposure to a known allergen for that patient — roughly 10-20% of anaphylaxis cases have no cutaneous signs at all.
Intramuscular epinephrine (0.01 mg/kg of the 1:1,000 concentration, maximum 0.3-0.5 mg) in the mid-anterolateral thigh is the only first-line, life-saving treatment; antihistamines and corticosteroids are adjuncts that must never delay it.
Epinephrine may be repeated every 5-15 minutes, and a meaningful proportion of children require a second or even third dose before symptoms resolve.
Biphasic reactions occur in roughly 1-20% of cases, usually within 1-4 hours of apparent resolution; risk rises with delayed initial epinephrine administration, need for more than one dose, and a severe initial presentation.
Observation after a mild reaction that fully resolves with a single epinephrine dose can be as short as 1-2 hours, while reactions with cardiorespiratory involvement or multiple epinephrine doses warrant at least 4-6 hours of monitoring.
Last updated: July 2026
- Anaphylaxis & Allergic Emergencies
- Defining Anaphylaxis: Diagnostic Criteria
Anaphylaxis is a severe, life-threatening systemic hypersensitivity reaction with rapid onset that can cause death through airway obstruction, bronchospasm, and/or circulatory collapse. The widely used clinical criteria (derived from National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network consensus work) state that anaphylaxis is highly likely when any one of the following three criteria is met:
Acute onset (minutes to hours) of illness involving skin and/or mucosal tissue (hives, itch/flush, swollen lips-tongue-uvula) AND at least one of:
- Respiratory compromise (dyspnea, wheeze/bronchospasm, stridor, hypoxemia)
- Reduced blood pressure or associated end-organ dysfunction (hypotonia, syncope, incontinence)
Two or more of the following occurring rapidly after exposure to a likely allergen for that patient:
- Skin/mucosal involvement
- Respiratory compromise
- Reduced blood pressure or associated symptoms
- Persistent gastrointestinal symptoms (crampy pain, vomiting)
Reduced blood pressure after exposure to a known allergen for that patient (minutes to hours):
Infants and children: low systolic blood pressure for age, or a drop of more than 30% from the child's baseline
This criterion alone is sufficient even with no skin findings at all — a critical exam trap, because roughly 10-20% of anaphylaxis cases present without any cutaneous signs.
Exam trap: Skin findings are the most common presentation but are not required for the diagnosis. A child with a known peanut allergy who develops sudden hypotension and vomiting after accidental exposure — with no rash whatsoever — still meets criterion 3 and must be treated as anaphylaxis.
First-Line Treatment: Intramuscular Epinephrine
Epinephrine is the only first-line, life-saving treatment for anaphylaxis. No other drug class reverses the underlying mediator release and hemodynamic collapse. Delay in epinephrine administration is the single strongest modifiable risk factor for biphasic reactions and fatal outcomes tested on this exam.
Dose: 0.01 mg/kg of the 1:1,000 (1 mg/mL) concentration, given intramuscularly (IM).
Maximum single dose: 0.3 mg for most children (some protocols allow up to 0.5 mg in larger adolescents).
Site: the mid-anterolateral thigh (vastus lateralis) — preferred over the deltoid because it achieves faster, more reliable peak plasma concentration.
Repeat dosing: every 5-15 minutes if symptoms persist or recur; many patients need a second dose, and a meaningful minority need three or more.
Fixed auto-injector doses commonly available in the region: 0.15 mg for children roughly 10-25 kg (junior auto-injector) and 0.3 mg for children/adults at or above roughly 25-30 kg.
Worked example: A 20 kg child (roughly 6 years old) develops facial angioedema, wheeze, and hypotension after a bee sting. The correct IM epinephrine dose is 0.01 mg/kg x 20 kg = 0.2 mg , drawn up as 0.2 mL of the 1:1,000 (1 mg/mL) solution and injected into the mid-anterolateral thigh. If a fixed-dose auto-injector is the only device available, the 0.15 mg junior device is the closer match for this weight and is an acceptable substitute for the adult 0.3 mg device.
Exam trap: Subcutaneous administration, intravenous (IV) push epinephrine outside a monitored resuscitation, and antihistamine-first management are all wrong answers the exam uses as distractors. IM epinephrine in the thigh, given immediately, is always the correct first step once anaphylaxis is suspected — do not wait to confirm with labs. Serum tryptase is a retrospective, confirmatory test and is never used to decide on initial treatment.
Biphasic Reactions and Observation Period
A biphasic reaction is recurrence of anaphylactic symptoms after apparent resolution, without any re-exposure to the trigger, typically within 1-4 hours but reported as late as 24-72 hours afterward. Reported incidence ranges roughly 1-20% depending on the population studied.
Risk factors for a biphasic reaction the exam expects you to recognize:
- Delayed initial epinephrine administration (more than 60 minutes from symptom onset)
- Need for more than one dose of epinephrine to control the initial reaction
- Severe initial presentation (for example, hypotension or respiratory compromise requiring intubation)
- Unknown trigger
Observation period guidance:
Uncomplicated, mild reactions that fully respond to a single epinephrine dose: roughly 1-2 hours of observation may be sufficient.
Reactions with any cardiorespiratory involvement, or requiring more than one epinephrine dose: at least 4-6 hours of observation is prudent, with some protocols recommending overnight admission for severe reactions.
All patients should be discharged with a prescription for (or access to) an epinephrine auto-injector , a written action plan, and referral to allergy/immunology.
Adjunct Therapies (Never First-Line)
These treat associated symptoms but do not replace epinephrine and must never delay it:
- Adjunct Role
- H1 antihistamine (e.g., diphenhydramine) Relieves itching/urticaria only; no effect on airway or hemodynamics
H2 antihistamine (e.g., ranitidine/famotidine) Added benefit for cutaneous symptoms; no proven mortality benefit
Systemic corticosteroid May reduce protracted or biphasic symptoms; onset takes hours, so it is useless for acute collapse
Inhaled bronchodilator (albuterol) Adjunct for persistent bronchospasm after epinephrine
IV crystalloid bolus (20 mL/kg) For hypotension refractory to IM epinephrine, alongside repeat epinephrine dosing or an epinephrine infusion
IV epinephrine infusion Reserved for refractory anaphylactic shock in a monitored setting, given the narrow therapeutic index and arrhythmia risk of IV push dosing
Note: chronic allergy evaluation, allergen avoidance counseling, and long-term immunotherapy are covered in the outpatient chronic allergy chapter — this section focuses solely on acute emergency management.